GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Pianista, just a year ago the SP was 2300 now it is 825. That is a decline of approx 65% but Hikma's balance sheet and cash generation is still extremely strong. Advair is delayed but so what, competitors applications have also been rejected so nobody is actually eating away into Hikma's potential market at the moment. Generics is a difficult sector but fortunately Hikma don't rely solely on Generics because they also have Branded and Injectables that are still highly profitable. Normally when a new CEO starts they like to clear the decks immediately and get all the bad news out of the way at the beginning of their tenure - - this is only natural because they are bulletproof for the first few months and it makes things look much better as time goes on for which they get the credit and nice bonuses. I think the more experienced fund managers will be waiting for the bad news (if any) to be announced and then when the SP drops again (no doubt) the feeding frenzy to buy Hikma will begin in earnest. The other thing that may happen is the results and forecasts will not be as bad as expected and the SP will leap up exponentially (see Provident).
Not sure why � signs are shown as "�" in my last post.
I know the feeling Jimbo: every time I've averaged down, it's dropped even further. Should I now buy �5k more at 820p, or wait for sub �8, I wonder..... Ironically, I originally bought Hikma because I was looking for a safe haven - not expecting to make a killing, but not expecting to lose much either. But it's turned into a nightmare - so far..... In the absence of information, the SP continues to be driven by pure speculation. But at the slightest indication of light at the end of the tunnel, this share will rebound again with a vengeance, above �10 and beyond. Let's hope the results on 14 March provide that light. The new CEO will also be free to buy, and show some faith in the company, once the results are announced.
i was tempted to top-up at 874p. but that was around my entry price so maybe i should hold off awhile. maybe i buy on friday if i have funds. 52 week low is 855.60p.
Bought another £5k today at £8.76 which i quickly regretted doing. Strangely, the SP stayed down even though shares purchased was 298,000 against 180,000 sold. Let's see what happens tomorrow.
Some fun and games going on here... AKO closing its short position (a bit) yesterday and some positive buying numbers today. Perhaps we have seen our share price low after all.
The main thing that HIK needs is the return of Obama-care or similar, right now generics are off the table in the US and will be for another 3 years.
Shares falling in anticipation of more poor results? As always we are the last to know. At least the short interest is way off the highs of c6% from last year. GLA
I will hold back until preliminary results before making any further buys. If AKO hadn’t increased its position I would be buying but clearly they are determined to push below the recent 840 low. Looking back to 2012 my chart suggests 776 as a near term target figure for shorters. Whatever happens this share can’t fall forever and it can turn on a sixpence. GLA
From the Bloomberg site....Sigurdur Oli Olafsson Ph.D. Age 48 Perhaps he�s been brought in to negotiate the Hikma takeover by ???
This sp is not going to last and imo it will spike up soon as all health checks of the company issolid and good dividends. Directors owns alot of shares . New ceo with excellent track record. What else an investor wants!? I added more today. This is only my opinion and not an advice to buy or sell or hold. GLA
Jimbo, he's definitely no more than around 50. I'm also going to ignore daily movements on this share: I'm in for the long haul. Lets hope for positive news on 14 March (prelims).
Correction. The alerts should be 9.00 and 9.60. I can't even keep up with the volatility of this share.
I did try to find out his DOB but couldn't see it mentioned anywhere. It definitely did say the reason he left Teva was retirement. He looks a lot older than mid forties, at a guess i would say he is in his sixties. I hope he doesn't see this post if he really is under 50. Anyway, I'm going to try and forget about Hikma for a while. I've set alerts up for 10.00 and 10.60 so it will be interesting to see which one triggers first.
I'm not sure he did "retire" from working life - he's only late 40s, I believe. He probably moved on for undisclosed political reasons. Anyway one would hope that Hikma gave him a thorough vetting before appointing him.
How can a share price leap by up to 15% on news of a new CEO and then be reversed in the space of two days with no obvious reason. It was a good appointment but i was a bit concerned that he actually left Teva to retire from working life. The fact that he has this frame of mind suggests to me that he will be lacking the drive needed to advance Hikma through some difficult times. He obviously doesn't need the money or the hassle and he will always have thoughts of leisurely pursuits constantly on his mind--that is a bit worrying.
AKO have enlarged their short to meet their target price. So now they will dip the price (785?) on the day of results and then, hopefully our coiled spring will be released.
This share is like a coiled spring. It was released yesterday and shot up 15% at one stage. It's now been wound back down. If we get good news on Advair and end of year results are not too bad then it will be released once again but without the winding back down. Incidentally, an analyst mentioned the fact that a trading statement didn't accompany the CEO announcement does suggest that the results will be in line with expectations which is a good thing.
this dropped away sharply in the closing 10 minutes... very suspicious and hardly attributable to profit takers
Disappointed that it fell back so much from today's high of 10.80. On the plus side it still finished up 45p and who wouldn't have settled for that before opening this morning. Hopefully, the fact that it did rise so quickly and easily today should tempt many more buyers to purchase these shares. Let's hope tomorrow is a good day.
I hope you do well Foxy... even the shorters will want to jump on to the rise if this is it
As much as like the company its turning out to be a great trading share.
buyers returning? retraced two thirds on the day
Given Siggi's track record and background he will probably have a stronger influence on the stock in the States. I picked up my first batch at �16 and have averaged down to I won't tell you where...
Having heavily averaged down from c�17, I'm now "only" 15% down on this share. I'm so happy! However, bracing myself for more volatility.....